MARKET

SYBX

SYBX

Synlogic
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.030
+0.010
+0.50%
After Hours: 2.050 +0.02 +0.99% 16:00 10/20 EDT
OPEN
2.030
PREV CLOSE
2.020
HIGH
2.060
LOW
1.970
VOLUME
82.00K
TURNOVER
--
52 WEEK HIGH
3.460
52 WEEK LOW
1.350
MARKET CAP
69.36M
P/E (TTM)
-1.2167
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Synlogic Appoints David Hava, Ph.D., as Chief Scientific Officer
Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the appointment of David Hava, Ph.D. as Chief Scientific Officer. Dr. Hava will provide strategic leadership to the research organization and build Synlogic&
PR Newswire · 09/14 12:00
We're Keeping An Eye On Synlogic's (NASDAQ:SYBX) Cash Burn Rate
Simply Wall St. · 09/10 19:15
7 Top Stocks Under $5
Penny stocks often get a bad rap for their low trading price, but many investors will tell you that they are actually some of the top stocks to buy. Although companies that trade at a low price range are often a victim of bad business decisions, the affordability of these stocks makes them an appealing
InvestorPlace · 08/28 14:37
2 Healthcare Stocks Under $5 That Could Deliver Triple-Digit Gains
It’s a game of high stakes and high-return potential. We’re talking about investing in bargain priced healthcare stocks. For some, the risk associated with these plays is enough to keep them away. That said, other market watchers see the opportunity at hand as too enticing to ignore.What makes these
TipRanks · 08/24 20:30
Synlogic Reports Second Quarter 2020 Financial Results and Provides Business Update
Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today reported financial results for the second quarter ended June 30, 2020, and provided an update on programs and progress.
PR Newswire · 08/06 11:00
Synlogic to Present at Upcoming Virtual Banking Conferences
Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that Aoife Brennan, M.B. Ch.B., Synlogic's president and chief executive officer, and other members of the executive
PR Newswire · 07/31 18:49
Synlogic Promotes Tony Awad To COO Role
Benzinga · 07/30 12:27
Synlogic Announces Promotion of Antoine 'Tony' Awad to Chief Operating Officer and Additions to Leadership Team
Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the promotion of Antoine 'Tony' Awad to the position of Chief Operating Officer. As Chief Operating Officer, Tony wi
PR Newswire · 07/30 11:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SYBX. Analyze the recent business situations of Synlogic through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SYBX stock price target is 7.25 with a high estimate of 13.00 and a low estimate of 2.000.
EPS
Institutional Holdings
Institutions: 85
Institutional Holdings: 23.13M
% Owned: 67.69%
Shares Outstanding: 34.17M
TypeInstitutionsShares
Increased
9
630.00K
New
30
152.20K
Decreased
20
2.00M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.90%
Pharmaceuticals & Medical Research
-0.28%
Key Executives
Chairman/Independent Director
Peter Barrett
President/Chief Executive Officer/Director
Aoife Brennan
Chief Financial Officer
Gregg Beloff
Other
David Hava
Other
Richard Riese
Other
Michael Slater
Independent Director
Michael Burgess
Independent Director
Patricia Hurter
Independent Director
Chau Khuong
Independent Director
Nick Leschly
Independent Director
Edward Mathers
Independent Director
Richard Shea
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SYBX
Synlogic, Inc., formerly Mirna Therapeutics, Inc., is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). It is also focused on Synthetic Biotic medicines to address other conditions, including inflammatory bowel disease , cancer and metabolic conditions, such as diabetes and obesity. The Company’s synthetic biotic medicines leverages the tools and principles of synthetic biology to genetically reengineer probiotic microbes to perform or deliver critical functions missing or damaged due to disease. The Company’s pipeline includes synthetic biotic medicines for the treatment of inborn errors of metabolism (IEM). It is developing SYNB1020 for the treatment of UCD and HE. It is developing SYNB1618 for the treatment of PKU.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Synlogic Inc stock information, including NASDAQ:SYBX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SYBX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SYBX stock methods without spending real money on the virtual paper trading platform.